Ask RED
Eddie Torreloma, NP has the most, with 282 of 698 visits. Next is Dr. Tilda Falken with 143, then Dr. Henry Falken with 89 and Dr. Conrad Eichen with 79.
Every visit at Fairhaven Clinical Group, LLC falls under a corporate refill policy, so each one counts as flagged.
He also stands out for something else: the records show him prescribing controlled drugs to patients in states where he has no license on record.
The records show indicators of it, not a verdict. A licensing board or a court decides that.
47 visits with patients in New York, Rhode Island, Tennessee and Florida, where he has no license on record, 43 of them by telehealth. Those visits produced 39 controlled prescriptions for 5 patients, with 119 fills authorized.
Every one is a Schedule II prescription with refills authorized, which federal law doesn’t allow, and 20 are written above the labeled daily maximum.
All five are Schedule II stimulants: lisdexamfetamine (30 mg and 70 mg), methylphenidate (10 mg and 36 mg ER) and dextroamphetamine-amphetamine 20 mg.
Take just lisdexamfetamine 70 mg. There are 10 prescriptions to 4 patients (NY, RI, TN, FL), 9 of them by telehealth, all on Schedule II.
Every prescription has 1 to 3 refills authorized, 32 fills in total. Federal law doesn’t allow refills on Schedule II. 5 of the 10 are written above the labeled maximum of 70 mg a day: 140 mg for the NY patient and 210 mg for the TN patient.
On the records he is licensed in Arizona, Kentucky, Maine and South Carolina. The prescriptions went to patients in New York (16 visits), Rhode Island (12), Florida (10) and Tennessee (9).
No DEA registration is on record for any of those patients’ states.
That comes from the records only, so each state board would need to confirm his license status.
This is an estimate for one small sample, not a total. For lisdexamfetamine 70 mg alone, Medicare and Medicare Advantage paid $999.77 on those 10 visits.
If each claim were treated as false, the usual measure is triple damages, about $3,000, plus a civil penalty per claim. At roughly $14,000 to $28,000 each, the theoretical ceiling is about $140,000 to $280,000. Counsel would need to confirm those figures.
Add the drugs themselves: 1,500 capsules were authorized, about 50 thirty-capsule fills. At a rough $100 (generic) to $450 (brand) per fill, that is another $5,000 to $22,000, my estimate. Across all his visits to unlicensed states, $4,003.13 was paid on 47 visits.
I’ve put the findings into a referral packet for Eddie: a summary, the evidence index, the prescription table, the exposure estimate and the next steps.
